Multiple sclerosis and COVID-19: How many are at risk?
Gabriel BstehChristina BitschnauHarald HegenMichael AuerFranziska Di PauliPaulus Stefan RommerFlorian DeisenhammerThomas BergerPublished in: European journal of neurology (2020)
In a population-based MS cohort, the proportion of patients at high risk of COVID-19 mortality is below 1%. Importantly, the vast majority of these MS patients did not receive any DMT.